GH Research (NASDAQ:GHRS) Sees Large Volume Increase - What's Next?

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 532,962 shares were traded during mid-day trading, an increase of 158% from the previous session's volume of 206,459 shares.The stock last traded at $14.70 and had previously closed at $16.69.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of GH Research in a research note on Friday, May 9th. JMP Securities reaffirmed a "market outperform" rating and set a $39.00 target price on shares of GH Research in a research note on Tuesday, June 24th. Guggenheim decreased their target price on shares of GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Cantor Fitzgerald assumed coverage on shares of GH Research in a research note on Wednesday, June 4th. They set an "overweight" rating and a $25.00 target price for the company. Finally, Wall Street Zen raised shares of GH Research from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

GH Research Price Performance

The company's 50-day moving average is $13.55 and its two-hundred day moving average is $11.74. The company has a market cap of $754.44 million, a P/E ratio of -18.35 and a beta of 0.96.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.42. Equities research analysts anticipate that GH Research PLC will post -0.8 EPS for the current year.

Institutional Investors Weigh In On GH Research

Hedge funds have recently modified their holdings of the business. Two Sigma Investments LP bought a new stake in shares of GH Research during the 4th quarter valued at $117,000. Millennium Management LLC bought a new stake in shares of GH Research during the 4th quarter valued at $145,000. BNP Paribas Financial Markets bought a new stake in shares of GH Research during the 4th quarter valued at $44,000. Northern Trust Corp lifted its stake in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after buying an additional 8,641 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in shares of GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after buying an additional 41,711 shares in the last quarter. Institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).